Periprocedural Variability of Platelet Functions in Carotid Artery Stenting: An Analysis Using VerifyNow

Masataka Yoshimura,^{1,2} Kazutaka Sumita,³ Shoko Fujii,³ Kazunori Miki,³ Yuki Aizawa,³ Kyohei Fujita,³ Shinji Yamamoto,² Shigeru Nemoto,³ and Taketoshi Maehara¹

Objective: The assessment of platelet functions is necessary to prevent both thromboembolic and hemorrhagic complications under dual antiplatelet therapy (DAPT). Using the VerifyNow (Accumetrics, Inc., San Diego, CA, USA) assay, this study aimed to reveal time-dependent changes in platelet functions after carotid artery stenting (CAS).

Methods: We enrolled retrospectively 43 patients who underwent CAS under DAPT. Aspirin reaction unit (ARU) and P2Y₁₂ reaction unit (PRU) values were determined on the day before and on days 1, 3, and 7 after the procedure. Multiple comparison tests (MCTs) were performed among ARU and PRU measurement points, and the proportions of hypo- and hyper-responses were compared.

Results: The median ARU values were 408 (interquartile range: 392–497) before CAS and 418 (405–470) on day 1, 405 (393.0–460.5) on day 3, and 402 (388.5–477.5) on day 7 (not significant in MCTs). The percentages of hypo-responses were 16.3%, 7.0%, 2.3%, and 7.0%, respectively ($p = 0.11$). The significantly different median PRU values were 173 (116.5–209.5), 233 (166.5–273.5), 139 (70.5–205.5), and 51 (9.0–79.5), respectively. The median PRU was before the procedure within the therapeutic range but exceeded the upper cutoff on day 1 and was below the lower cutoff on day 7. The percentages of hypo-responses were 14.0%, 51.2%, 18.6%, and 11.6%, respectively ($p < 0.001$) and the percentages of hyper-responses were 9.3%, 2.3%, 23.3%, and 62.8%, respectively ($p < 0.001$).

Conclusion: In the periprocedural CAS period, ARU values were stable, but PRU values showed time-dependent changes. PRU values were above the therapeutic range the day after CAS but decreased below this range on day 7.

Keywords ▶ carotid artery stenting, platelet function, VerifyNow

Introduction

Carotid artery stenosis is a major cause of ischemic stroke, and carotid endarterectomy is an established treatment to prevent stroke. In recent years, carotid artery stenting

(CAS) has provided a less invasive alternative, especially in endarterectomy high-risk patients.¹⁾ Although emboli protection devices are effective in CAS, the procedure requires attention to thromboembolic complications such as in-stent thrombosis and acute stent occlusion in the perioperative period.²⁾ Therefore, the administration of antiplatelet drugs is important in CAS during the periprocedural period to prevent thromboembolic complications.³⁾ Dual antiplatelet therapy (DAPT) with clopidogrel plus low-dose aspirin is recommended because each drug inhibits the platelet function via a different pathway. When using antiplatelet drugs, we should pay attention to insufficient antiplatelet effects causing thromboembolic complications during endovascular treatment. This effect is termed “hypo-response,” also known as “high on-treatment platelet reactivity” or “resistance.”^{4–11)} Besides, DAPT increases the risk of life-threatening hemorrhagic complications.¹²⁾ Therefore, we need to manage DAPT in the optimum range to prevent not only thromboembolic but also hemorrhagic complications.

¹Department of Neurosurgery, Tokyo Medical and Dental University, Tokyo, Japan

²Department of Neurosurgery, Tsuchiura Kyodo General Hospital, Tsuchiura, Ibaraki, Japan

³Department of Endovascular Surgery, Tokyo Medical and Dental University, Tokyo, Japan

Received: September 3, 2020; Accepted: October 31, 2020

Corresponding author: Masataka Yoshimura, Department of Neurosurgery, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo 113-8519, Japan

Email: mstktksm@yahoo.co.jp

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives International License.

©2021 The Japanese Society for Neuroendovascular Therapy

Conventional methods for assessing platelet function are complicated and difficult to standardize. The VerifyNow (Accumetrics, Inc., San Diego, CA, USA) assay analyses platelet functions quickly and easily.⁴⁾ Many studies using VerifyNow have provided useful evidence about hypo-response to aspirin or clopidogrel,^{4–11,13–17)} as well as hyper-response to clopidogrel.^{4,13,18)} Recently, dynamic variability in response to clopidogrel after endovascular treatment has been reported^{10,18–23)}; however, individual changes in platelet functions in the short period under DAPT have not been described yet. Using the VerifyNow assay, this study aimed to reveal how and why platelet functions in CAS patients change in the periprocedural period.

Materials and Methods

Patient population

This study was approved by the ethical review board of each study institution and was conducted in accordance with the Declaration of Helsinki. All patients gave written informed consent for their participation in the study. Patients who underwent CAS for carotid artery stenosis at these institutes between March 2013 and August 2018 were enrolled in this study. Patients who underwent CAS for carotid artery dissection or restenosis after CAS were excluded. Thus, we obtained chronological VerifyNow data from 51 patients. Another exclusion criterion was insufficient antiplatelet pretreatment before the procedure. Sufficient antiplatelet pretreatment was defined as more than 7 d of 100 mg/d aspirin and 14 d of 75mg/d clopidogrel. Eight patients were excluded based on this criterion. There was no control group in this study.

Methods

Using VerifyNow, we determined the parameters aspirin reaction unit (ARU) and P2Y12 reaction unit (PRU) at day 1 before and days 1, 3, and 7 after the CAS procedure. Blood samples of the patients were collected into 2.0 mL 3.2% sodium citrate tubes from the median cubital vein or an arterial line inserted in the radial artery. All VerifyNow measurements were performed within 2 hours of sampling. Using the commonly accepted cutoff values of 550 ARU, aspirin responses above 550 were defined as hypo-response. For clopidogrel, PRU results above 230 were defined as hypo-response,⁵⁾ in the range of 70–230 as normal response, and below 70 as hyper-response.¹³⁾

To determine factors affecting the initial state of response to DAPT and changes in platelet functions, the following

data were recorded: age, sex, presence of hypertension, diabetes, hyperlipidemia, coronary artery disease, and current smoking at the time of recording, administration of statins, proton pump inhibitors, cilostazol, and oral anti-coagulants, preoperative laboratory values including serum albumin, hemoglobin, and platelets, symptomatic or asymptomatic lesion, and percentage of stenosis using the North American Symptomatic Carotid Endarterectomy Trial (NASCET) method.²⁴⁾ Appearance of diffusion-weighted image (DWI)-positive lesions, symptomatic ischemic complications and hemorrhagic complications were also recorded and the relation between responsiveness at each measurement point and the occurrence of symptomatic complications and the appearance of DWI-positive lesions were analyzed.

CAS procedure

Almost all procedures were performed under general anesthesia apart from 1 case in which general anesthesia was undesirable. An arterial line was placed into the radial artery for invasive arterial pressure monitoring in all cases. A guiding catheter was inserted from the right or left femoral artery after systemic heparinization with a target activated clotting time of 250–300 s. If we experienced difficulties with this femoral approach, we chose the radial approach. Emboli protection devices were selected by the operator but were used in all cases. We used the Carotid Wallstent (Boston Scientific, Natick, MA, USA) which has a closed-cell design except in cases with highly curved lesions, where we employed stents with open-cell design (Precise; Cordis, Miami, FL, USA and Protégé RX; Medtronic, Minneapolis, MN, USA). Predilation of the stenotic lesion by a percutaneous trans-arterial balloon was only performed if the stent delivery system failed to pass through the lesion. After the procedure, systemic heparinization was discontinued, and DAPT was maintained for at least 2 months. We did not add antiplatelet dosages according to the test results unless there was an ischemic complication after the stenting procedure.

Statistical analysis

Continuous variables were analyzed using the Mann–Whitney U test and categorical variables using Fisher's exact test to compare between two groups. For multiple comparisons among either ARU or PRU values at different time points, the Wilcoxon signed-rank test adjusted by Holm's method was used. Cochran's Q test was used to compare the proportions of cases judged as hypo-response and hyper-response. If there was a statistically significant

Table 1 Summary of baseline characteristics

Variable	Study cohort (n = 43)
Age, years	72.0 (68.0–76.5)
Female sex	6 (14.0%)
Hypertension	36 (83.7%)
Diabetes mellitus	17 (39.5%)
Hyperlipidemia	23 (53.5%)
Coronary artery disease	2 (4.7%)
Current smoking	12 (27.9%)
Statin	34 (79.1%)
Proton pump inhibitor	36 (83.7%)
Cilostazol	2 (4.7%)
Oral anti-coagulant	3 (7.0%)
Duration of clopidogrel use before treatment, days	27 (18.5–85.5)
Hemoglobin, g/dL	13.9 (12.6–14.5)
Platelets, $\times 10^3/\text{mL}$	21.2 (18.6–25.6)
Serum albumin, mg/dL	4.2 (3.9–4.4)
Symptomatic lesion	21 (48.8%)
NASCET, %*	69.3 (62.5–79.9)
General anesthesia	42 (97.7%)
9-Fr guiding catheter	36 (83.7%)
Closed stent	35 (81.4%)
Flow reversal	35 (81.4%)

Continuous variables are presented as median (interquartile range). * The degree of carotid artery stenosis measured using the NASCET method. NASCET: North American Symptomatic Carotid Endarterectomy Trial

difference between any of the measuring time points, the difference between the preprocedural value and the value at the measuring time point (delta PRU) was determined, and the factors affecting the difference were analyzed using multiple regression analysis. Statistical analysis was performed using R 3.3.3 GUI 1.69 Mavericks build (7328), and $p < 0.05$ was defined to be significantly different.

Results

The patient characteristics are summarized in **Table 1**. The median age of the 43 enrolled patients was 72.0 years (interquartile range: 68.0–76.5 years) including 37 males (86.0%) and 6 females (14.0%). Of the 43 patients, 21 (48.8%) presented initially with ischemic events ipsilateral to the ICA stenosis. The median stenosis degree was 69.3 (62.5–79.7) according to the NASCET method. All procedures were performed under DAPT consisting of 100 mg/d aspirin and 75 mg/d clopidogrel. In two cases (4.7%), 200 mg/d cilostazol was also administered. Oral anticoagulants in addition to DAPT were administered in three patients (7.0%). The median duration of oral clopidogrel administration before the stenting procedure was 27 d (interquartile range: 18.5–85.5 d).

In 42 patients (97.7%), CAS was performed under general anesthesia, and in one patient (2.3%) under local anesthesia. A 9-Fr guiding catheter was used in 36 patients (83.7%), whereas in the remaining seven patients (16.3%), either a 6-Fr ultra-long sheath or an 8-Fr guiding catheter was used. In 37 (86.0%) and 6 (14.0%) patients, CAS was performed via the femoral and right radial artery, respectively. Regarding emboli protection devices, a flow reversal system was used in 35 patients (81.4%), distal protection in seven patients (16.3%), and proximal protection in one patient (2.3%). Closed- and open-cell stents were used in 35 (81.4%) and 8 (18.6%) patients, respectively.

Periprocedural complications were recorded in three cases (7.0%). In one patient, it was a transient ischemic attack, and two patients presented cerebral infarction. One of them had improved symptoms at discharge; the other patient's neurological deficits became permanent. In 14 patients (32.6%), high signal intensity spots appeared in DWI taken the day after the CAS procedure. There were no hemorrhagic complications. The overall morbidity and mortality rates were 2.3% and 0%, respectively.

According to preprocedural ARU and PRU values determined by VerifyNow, seven patients (16.3%) were categorized as hypo-response to aspirin, six patients (14.0%) as

Table 2 Comparison of the patient characteristics between aspirin reaction unit hypo-response and normal response

Variables	Hypo-response n = 7	Normal response n = 36	p value
Age, years	73 (69.5–77)	72 (68.0–77.0)	0.97
Female sex	1 (14.3%)	5 (13.9%)	1
Hypertension	7 (100%)	29 (80.6%)	0.58
Diabetes mellitus	5 (71.4%)	12 (33.3%)	0.09
Hyperlipidemia	4 (57.1%)	19 (52.8%)	1
Coronary artery disease	0 (0%)	2 (5.6%)	1
Current smoking	0 (0%)	12 (33.3%)	0.16
Statin	6 (85.7%)	28 (77.8%)	1
Proton pump inhibitor	7 (100%)	29 (80.6%)	0.58
Cilostazol	2 (28.6%)	0 (0%)	0.02†
Oral anti-coagulant	2 (28.6%)	1 (2.8%)	0.06
Hemoglobin, g/dL	14.1 (12.4–14.2)	13.5 (12.6–14.6)	0.55
Platelets, $\times 10^3/\text{mL}$	21.7 (18.5–22.9)	21.2 (18.7–26.3)	0.61
Serum albumin, mg/dL	4.2 (3.7–4.4)	4.3 (3.9–4.4)	0.43
Preprocedural PRU	160 (94.0–219.5)	177 (118.8–209.3)	0.52
Symptomatic lesion	5 (71.4%)	16 (44.4%)	0.24
NASCET, %*	80.2 (71.0–86.2)	66.3 (59.5–78.0)	0.047‡

Continuous variables are presented as median (interquartile range). * The degree of carotid artery stenosis measured using the NASCET method. † Statistically significant in Fisher's exact test. ‡ Statistically significant in the Mann-Whitney U test. NASCET: North American Symptomatic Carotid Endarterectomy Trial; PRU: P2Y12 reaction unit

hypo-response to clopidogrel, and four patients (9.3%) as hyper-response to clopidogrel. Thus, 33 patients (76.7%) were within the therapeutic PRU range. Characteristics comparison between hypo-response and normal or hyper-response patients to aspirin and clopidogrel are shown in **Tables 2** and **3**. In the group with ARU hypo-response, co-administration of cilostazol was more frequent (28.6% vs. 0%, $p = 0.023$), and the NASCET degree of stenosis was higher (80.2% [71.0–86.2%] vs. 66.3% [59.5–78.0%], $p = 0.047$). In the PRU hypo-response group, the levels of hemoglobin (10.5 g/dL [10.1–11.0 g/dL] vs. 14.1 g/dL [13.1–14.5 g/dL], $p = 0.01$) and serum albumin (3.4 mg/dL [2.8–3.6 mg/dL] vs. 4.3 mg/dL [4.1–4.4 mg/dL], $p < 0.001$) were significantly decreased.

Individual changes in ARU and PRU values are shown in **Fig 1A** and **1B**. The median preprocedural ARU value was 408 (392–497), and the median post-procedural ARUs were 418 (405.0–470.0) on day 1, 405 (393.0–460.5) on day 3, and 402 (388.5–477.5) on day 7. The median ARU values were below the cutoff at all measured time points, and the multiple comparison test (MCT) did not reveal

any statistically significant differences among these values. The percentages of patients classified as hypo-response were 16.3% before CAS, 7.0% on day 1, 2.3% on day 3, and 7.0% on day 7 with no significant group differences according to Cochran's Q test ($p = 0.11$). The median preprocedural PRU value was 173 (116.5–209.5) compared to median post-procedural PRUs of 233 (166.5–273.5) on day 1, 139 (70.5–205.5) on day 3, and 51 (9.0–79.5) on day 7. The median PRU ranged between the upper and lower cutoff values before the procedure and on day 3; however, on day 1, the median PRU exceeded the upper cutoff, whereas it was below the lower cutoff value on day 7. The MCT revealed significant differences between day 0 and day 1, as well as day 0 and day 7. The percentages of cases categorized as hypo-response were significantly different ($p < 0.001$, Cochran's Q test) with 14.0% before CAS, 51.2% on day 1, 18.6% on day 3, and 11.6% on day 7. Similar significant differences ($p < 0.001$) were revealed for the percentages of hyper-responses with 9.3% before CAS, 2.3% on day 1, 23.3% on day 3, and 62.8% on day 7.

Table 3 Comparison of the patient characteristics between P2Y12 reaction unit hypo-response and normal or hyper-response

Variables	Hypo-response n = 6	Normal or hyper-response n = 37	p value
Age, years	72 (71–76)	72 (68–76)	0.69
Female sex	2 (33.3%)	4 (10.8%)	0.19
Hypertension	4 (66.7%)	32 (86.5%)	0.25
Diabetes mellitus	3 (50.0%)	14 (37.8%)	0.67
Hyperlipidemia	4 (66.7%)	19 (51.4%)	0.67
Coronary artery disease	0 (0%)	2 (5.4%)	1
Current smoking	1 (16.7%)	11 (29.7%)	0.66
Statin	4 (66.7%)	30 (81.1%)	0.59
Proton pump inhibitor	5 (83.3%)	31 (83.8%)	1
Cilostazol	0 (0%)	2 (5.4%)	1
Oral anti-coagulant	0 (0%)	3 (8.1%)	1
Duration of clopidogrel use before treatment, days	22 (18.0–26.8)	41 (20.0–88.0)	0.25
Hemoglobin, g/dL	10.5 (10.1–11.0)	14.1 (13.1–14.5)	0.01†
Platelets, $\times 10^3/\text{mL}$	17.4 (15.0–25.5)	21.5 (19.1–25.3)	0.20
Serum albumin, mg/dL	3.4 (2.8–3.6)	4.3 (4.1–4.4)	<0.001†
Preprocedural ARU	422.5 (411.5–520.5)	406.0 (388.0–494.0)	0.10
Symptomatic lesion	5 (83.3%)	16 (43.2%)	0.09
NASCET, %*	74.6 (66.1–88.4)	69.3 (59.6–78.9)	0.21

Continuous variables are presented as median (interquartile range). *The degree of carotid artery stenosis measured using the NASCET method.

†Statistically significant in the Mann–Whitney U test. ARU: aspirin reaction unit; NASCET: North American Symptomatic Carotid Endarterectomy Trial

There was neither statistically significant relation between ARU nor PRU responsiveness at each measured time point and clinical adverse events (**Table 4**).

Next, we performed multiple regression analyses to presume the factors affecting individual PRU changes between the value before CAS and the value on day 1 or day 7, respectively. Due to the small case number, the purpose of this analysis was merely to consider the possibility. The results of the multiple regression analysis are shown in **Tables 5** and **6**. Regarding the differences between PRU values before the CAS and on day 1, the preprocedural ARU value, the NASCET degree of stenosis, and serum albumin level were extracted as possible factors. On the other hand, none was extracted as a possible factor of the difference between PRU values prior to CAS and on day 7.

Discussion

To balance the risk between hemorrhagic and ischemic complications, interventional procedures recommend

monitoring the platelet function and adjusting the dosages of antiplatelet agents. The high level of variability in antiplatelet response to aspirin and clopidogrel among patients is well recognized. However, there are few reports about individual changes in antiplatelet response during neurointerventional procedures. In this CAS study, individual ARU values were stable over time; however, the PRU values varied in the periprocedural period. The median PRU values on day 1 and day 7 after CAS were outside the defined normal range. Although 76.7% of patients were before CAS within the therapeutic clopidogrel range, 51.2% of cases were categorized as hypo-response on day 1 after CAS, whereas 62.9% of cases were classified as hyper-response on day 7. We successfully placed the stent in all enrolled patients, and a permanent periprocedural complication occurred in only one patient (2.3%). The results of the JR-NET3, a nationwide survey in Japan, showed that the incidence of clinically significant complications is 2.3%.²⁵⁾ Therefore, our clinical treatment results are acceptable, and the data on antiplatelet agents can be used for further analyses.

Fig. 1 Time-dependent changes in ARU and PRU values. **(A)** ARU changes. The dotted line indicates the cutoff value. No significant differences between any of these values were detected (Wilcoxon signed-rank test adjusted by Holm's method). **(B)** Changes in PRU values. The dotted lines indicate upper and lower cutoff values. All combinations of time points differ significantly (Wilcoxon signed-rank test adjusted by Holm's method). ARU: aspirin reaction unit; PRU: P2Y12 reaction unit

Factors causing preprocedural hypo-response to antiplatelet drugs

Various predictors for hypo-response to aspirin such as increased body weight, body mass index, and proteinuria have been reported.^{6,7)} In the present study, co-administration of cilostazol and a higher NASCET degree of stenosis were more frequent in the ARU hypo-response group. A double-blind randomized multi-center trial in Korea revealed that cilostazol add-on to aspirin in ischemic stroke patients made no significant difference in the percentage of aspirin resistance compared to placebo⁸⁾; however, the mean ARU value before treatment had the tendency to be higher in the cilostazol group. Since the co-administration of cilostazol was in our study only observed in two patients, further investigations are warranted. The literature does not describe a correlation between the degree of carotid artery stenosis and ARU values. In carotid artery stenosis, aspirin is administered to prevent the progress of the stenosis. The ARU values are likely to be increased in patients with severe stenosis because the stenosis in some aspirin hypo-responders may progress to a CAS indication.

Numerous factors such as age, sex, hypertension, diabetes mellitus, obesity, and *CYP2C19* polymorphism have been reported as predictors for hypo-response to clopidogrel.^{14,15)} Current smoking, as well as levels of hemoglobin, cholinesterase, and serum albumin, have been also reported to be correlated with hypo-response to clopidogrel.^{9,16,17)} In the present study, age, sex, hypertension, diabetes mellitus, and smoking did not correlate with hypo-response to clopidogrel; however, the levels of hemoglobin and serum albumin were significantly lower in the PRU hypo-response group.

Individual ARU and PRU changes and their predictors

Multiple repeat measurements of the VerifyNow assay in healthy volunteers who did not take antiplatelet drugs revealed that PRU values varied widely intraindividually in contrast to ARU values.²⁶⁾ There are some reports regarding the variability of ARU and PRU values during periprocedural periods of endovascular treatments,^{10,18,21–23)} but most investigated the relatively long-term variability such as more than 1 week to 6 months after treatment.^{10,18,21)} Khanna et al. measured ARU and PRU values in patients after percutaneous coronary intervention (PCI) at discharge and 1 week, 1 month, 3 months, and 6 months after discharge. They describe that the ARU was unchanged for the study period but the PRU was significantly increased at 1 month after discharge with no significant changes afterward.¹⁰⁾ Tello-Montoliu et al. compared the PRU values of patients undergoing PCI at discharge, 3 months, and 6 months. These authors report that the PRU tended to be higher after 3 months than at discharge, and there was no difference between 3 months and 6 months.²¹⁾ Watanabe et al. compared PRUs at 7 d and 30 d after transcatheter aortic valve implantation and reported that the PRUs were not significantly different (136.7 ± 73.4 and 150.4 ± 83.2 , respectively, $p = 0.13$).¹⁸⁾ Patients included in their study had taken aspirin 100 mg/d for 7 d or more and either clopidogrel 75 mg/d for 7 d or more or alternatively loading with 300 mg followed by 75 mg/d before the treatment. These reports indicate that the ARU is stable over time, whereas the PRU stabilizes after 1 week or more after the procedure.

Regarding the short-term variability in PRU values, they were in another study significantly decreased 4 h after

Table 4 Relations of aspirin reaction unit or P2Y12 reaction unit responsiveness and symptomatic complication or appearance of DWI-positive lesion

Variables	Symptomatic complication			Appearance of DWI-positive lesion		
	(+) (n = 3)	(-) (n = 40)	P	(+) (n = 14)	(-) (n = 29)	P
ARU hypo-response						
Preprocedural	0 (0%)	7 (17.5%)	1	2 (14.3%)	5 (17.2%)	1
On day1	0 (0%)	3 (7.5%)	1	0 (0%)	3 (10.3%)	1
On day3	0 (0%)	1 (2.5%)	1	1 (7.1%)	0 (0%)	0.33
On day7	0 (0%)	3 (7.5%)	1	0 (0%)	3 (10.3%)	0.54
PRU hypo-response						
Preprocedural	0 (0%)	6 (15.0%)	1	1 (7.1%)	5 (17.2%)	0.65
On day1	2 (66.7%)	20 (50.0%)	1	7 (50.0%)	15 (51.7%)	1
On day3	1 (33.3%)	7 (17.5%)	0.47	4 (28.6%)	4 (13.8%)	0.40
On day7	1 (33.3%)	4 (10.0%)	0.32	2 (14.3%)	3 (10.3%)	1
PRU hyper-response						
Preprocedural	0 (0%)	4 (10.0%)	1	2 (14.3%)	2 (6.9%)	0.59
On day1	0 (0%)	1 (2.5%)	1	1 (7.1%)	0 (0%)	0.33
On day3	0 (0%)	10 (25.0%)	1	3 (21.4%)	7 (24.1%)	1
On day7	2 (66.7%)	25 (62.5%)	1	9 (64.3%)	18 (62.1%)	1

ARU: aspirin reaction unit; DWI: diffusion-weighted image; PRU: P2Y12 reaction unit

PCI compared to values before PCI, and there was no significant difference between 4 and 24 h after PCI.²²⁾ The difference between these and our results may be explained by the presence or absence of premedication. In their study, the premedication was a loading dose of 300 mg clopidogrel just before the PCI, whereas in our study, CAS was performed after a sufficiently long premedication period of more than 1 week for aspirin and 2 weeks for clopidogrel. The findings by Lee et al. regarding stenting for cerebral artery stenosis are similar to our results.²³⁾ In their study, the median ARU increased after stenting from 418 (range: 350–586) to 469 (range: 389–573; $p = 0.045$) and the median PRU from 256 (range: 56–325) to 274 (range: 81–370; $p = 0.018$). Their patients had taken 100 mg/d aspirin and 75 mg/d clopidogrel for 5 d or a loading dose of 300–500 mg aspirin and 300 mg clopidogrel before the stenting procedure.

One of the reasons why PRU values are elevated 24 h after a procedure might be that stenting procedures are invasive to blood vessel walls. In our study, an arterial line was inserted, and a relatively large-diameter catheter was used for stent delivery and distal embolic protection in almost all patients. Besides, CAS is a procedure that presses metal into the vessel wall and involves dilation of

the vessel by a balloon. Muller et al. suggest increased platelet reactivity in the presence of impaired endothelial functions.²⁷⁾ The CAS-induced damage to the endothelium may activate platelets, which may explain why the PRU was elevated on day 1. Schofer et al. reported that DWI-positive lesions increased over time after CAS.²⁸⁾ MRIs were taken twice at a mean of 3.5 h and 18 h after CAS, and DWI-positive lesions appeared in 20% and 32% of the patients, respectively. Moreover, in 5% of the cases, the number of DWI-positive lesions were increased in the second image. Among 111 patients undergoing CAS in the publication by Qureshi et al., perioperative ischemic complications occurred in 14 patients—in 4 patients during the procedure and in 10 patients within 48 h after the procedure.²⁹⁾ Both reports demonstrate that CAS-induced thromboembolic complications appear after rather than during the procedure, which may be explained by PRU increases on day 1. The values on day 1 might be affected by differences in perioperative management such as perioperative infusions, bleedings from puncture site and connector, or blood samples drawn from the arterial line. However, there were no significant differences between the ARU value on day 1 and those at other time points. We suggest that the perioperative management had little effect on PRU values.

Table 5 Multiple regression analysis for differences between PRU on day 1 and preprocedural PRU

	Regression coefficient estimate	Standard error	Lower 95% CI	Upper 95% CI	Standardized regression coefficient estimate	t-value	p value	VIF
(Intercept)	-351.252	148.955	-656.881	-45.622		-2.358	0.026	†
Age	0.434	1.081	-1.783	2.652	0.060	0.402	0.691	1.373
Female	29.762	17.504	-6.152	65.677	0.248	1.700	0.101	1.299
Hypertension	-19.617	18.632	-57.847	18.613	-0.174	-1.053	0.302	1.671
Diabetes mellitus	-1.188	13.202	-28.276	25.899	-0.014	-0.090	0.929	1.471
Hyperlipidemia	10.851	13.464	-16.774	38.477	0.130	0.806	0.427	1.593
Current smoking	-5.757	13.964	-34.408	22.894	-0.062	-0.412	0.683	1.385
Statin	-16.355	16.064	-49.316	16.606	-0.160	-1.018	0.318	1.508
Proton pump inhibitor	-19.068	19.216	-58.496	20.361	-0.169	-0.992	0.330	1.777
Hemoglobin	5.744	4.978	-4.470	15.958	0.228	1.154	0.259	2.388
Platelets	0.367	1.128	-1.947	2.681	0.057	0.325	0.747	1.846
Serum albumin	35.094	16.724	0.779	69.409	0.446	2.098	0.045	2.755†
Preprocedural ARU	0.253	0.090	0.068	0.437	0.445	2.808	0.009	1.533†
Preprocedural PRU	0.069	0.110	-0.156	0.294	0.115	0.627	0.536	2.064
Symptomatic lesion	-16.551	12.546	-42.292	9.191	-0.199	-1.319	0.198	1.389
NASCET*	0.956	0.437	0.058	1.853	0.336	2.185	0.038	1.440†

*The degree of carotid artery stenosis measured using the NASCET method. †Statistically significant. ARU: aspirin reaction unit; CI: confidence interval; NASCET: North American Symptomatic Carotid Endarterectomy Trial; PRU: P2Y12 reaction unit

Table 6 Multiple regression analysis for differences between PRU on day 7 and preprocedural PRU

	Regression coefficient estimate	Standard error	Lower 95% CI	Upper 95% CI	Standardized regression coefficient estimate	t-value	p value	VIF
(Intercept)	192.274	335.954	−497.047	881.593		0.572	0.572	
Age	−1.069	2.438	−6.071	3.932	−0.079	−0.439	0.664	1.373
Female	−3.897	39.478	−84.899	77.106	−0.017	−0.099	0.922	1.299
Hypertension	−41.776	42.023	−128.000	44.449	−0.197	−0.994	0.329	1.671
Diabetes mellitus	8.635	29.775	−52.458	69.728	0.054	0.290	0.774	1.471
Hyperlipidemia	−10.858	30.367	−73.165	51.449	−0.069	−0.358	0.723	1.593
Current smoking	−26.379	31.494	−90.998	38.240	−0.151	−0.838	0.410	1.385
Statin	33.497	36.231	−40.844	107.837	0.174	0.925	0.363	1.508
Proton pump inhibitor	−26.924	43.341	−115.851	62.004	−0.127	−0.621	0.540	1.777
Hemoglobin	−11.703	11.227	−34.740	11.334	−0.247	−1.042	0.307	2.388
Platelets	−1.337	2.543	−6.555	3.882	−0.109	−0.526	0.604	1.846
Serum albumin	−4.955	37.720	−82.349	72.440	−0.033	−0.131	0.897	2.755
Preprocedural ARU	0.065	0.203	−0.351	0.481	0.061	0.320	0.751	1.533
Preprocedural PRU	−0.496	0.247	−1.003	0.011	−0.441	−2.006	0.055	2.064
Symptomatic lesion	−46.057	28.295	−104.114	12.001	−0.294	−1.628	0.115	1.389
NASCET*	1.642	0.987	−0.382	3.666	0.306	1.665	0.108	1.440

*The degree of carotid artery stenosis measured using the NASCET method. There is no statistically significant difference. ARU: aspirin reaction unit; CI: confidence interval; NASCET: North American Symptomatic Carotid Endarterectomy Trial; PRU: P2Y12 reaction unit

As possible factors affecting PRU increases on day 1, the preprocedural ARU value, NASCET degree of stenosis, and serum albumin level were extracted. Buch et al. and Lev et al. found a positive correlation between ARU and PRU levels.^{11,30} The mechanism of this correlation is unknown; however, patients with poor aspirin response may have reduced responsiveness to clopidogrel. The NASCET degree of stenosis was in the current study correlated with the preprocedural ARU value, which might be the reason why the NASCET degree of stenosis was also correlated with increases in PRU. Serum albumin has been reported as a predictor for hypo-response to clopidogrel,^{9,17} and in our results, albumin was significantly lower in the preprocedural hypo-response group. This low serum albumin level may reflect a decrease in liver functions, and various drugs used in general anesthesia may have further inhibited the clopidogrel metabolism.

The ARU values did not change on day 3 and day 7, whereas PRU values decreased significantly from day 1 to day 3 and from day 3 to day 7. Moreover, the PRU values on day 7 were significantly different from preprocedural values. Several reports have already pointed out that PRU values are decreased after treatment.^{19,20} Delgado Almanoz et al. reported a delayed conversion into hyper-response to clopidogrel.¹⁹ In their study, 36 patients who underwent endovascular treatment for unruptured cerebral aneurysm consistently received 75mg/d clopidogrel during the study period and received repeated VerifyNow assay on the day before treatment and 30–40 d after initiation of clopidogrel administration. In these patients, mean duration of administration before first test and follow-up test were 8.8 d and 30.2 d, respectively. Two of 36 patients were considered hyper-response and 34 patients were within the therapeutic range (60–240) in the first test; however, 20 of these 34 patients (58.8%) converted to hyper-response in follow-up test. Kayan et al. verify the efficacy of a two-test protocol for achieving therapeutic response to clopidogrel prior to endovascular intracranial aneurysm treatment.²⁰ Patients received clopidogrel 17 d before treatment, and PRU was measured twice before the procedure. In the first and second tests, 71.8% and 89.3% of the patients, respectively, were within the range of the test but 51 of the 82 enrolled patients (62.2%) converted into hyper-responders in the postoperative test. According to these results, the responsiveness to clopidogrel may change depending on the duration of clopidogrel administration. In the current study, the duration of oral clopidogrel administration was at least 14 d, and the median duration from clopidogrel initiation to the first VerifyNow test was 27 d. The duration

of the premedication was sufficient; however, the PRU value on day 7 was significantly decreased compared to the preprocedural value, and more than half of the patients were hyper-responsive to clopidogrel. This delayed conversion to clopidogrel hyper-response may not have been caused by the duration of clopidogrel use but by the intervention itself. In our study, none was extracted as a possible factor affecting PRU decreases on day 7. Kayan et al. who were mentioned above performed a multiple logistic regression analysis to identify predictors of delayed conversion into hyper-response in their study; however, none was found.²⁰ They hypothesized that postoperative hyper-response might be induced, possibly related to a postoperative change in hepatic clopidogrel metabolism related to general anesthesia or the physiological stress of the procedure.

In this study, only one permanent symptomatic ischemic complication and no hemorrhagic complication occurred and no correlation was found between complications and PRU values; however, various authors have reported that higher PRU values correlated with ischemic complications and lower PRU values with hemorrhagic complications.^{4,13,18,19} From our results, PRU values are likely to decrease after stenting procedures. Thus, we need to be careful not to induce hemorrhagic infarctions. PRU evaluations should be timely to allow appropriate adjustments of antiplatelet drugs. Since there were no significant ARU changes, no further monitoring would be needed for cases showing normal responses before the CAS procedure.

Limitations

There are several limitations to this study. First, it had a retrospective design, and the sample size was small. Second, one patient (2.3%) had permanent ischemic sequelae, and 14 patients (32.6%) presented high signal intensity spots in DWIs taken on the day after CAS. Due to the small sample size, correlations with PRU values could not be determined. Further studies are needed to reveal whether individual PRU values are correlated with clinical outcomes or not. Third, we do not survey *CYP2C19* polymorphisms, a strong predictor of clopidogrel hypo-response.¹⁵ Additional studies are required to examine correlations between *CYP2C19* polymorphisms and time-dependent PRU variability.

Conclusion

This study evaluated periprocedural platelet functions using VerifyNow in patients undergoing CAS. The individual

ARU values were stable throughout the entire measurement period. By contrast, PRU values varied substantially; they exceeded the upper cutoff value on the day following the CAS procedure but were decreased below the lower cutoff value on the seventh postprocedural day. PRU evaluations should be timely to allow appropriate adjustments of antiplatelet drugs. Since there were no significant ARU changes, no further monitoring would be needed for cases showing normal responses before the CAS procedure.

Acknowledgment

The authors thank Dr. Masako Akiyama, Ph.D., Medical Innovation Promotion Center, Tokyo Medical and Dental University for her advice on the statistical analyses. This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. We would like to thank Editage (www.editage.com) for English language editing.

Disclosure Statement

The authors report no conflicts of interest concerning the materials or methods used in this study or the findings specified in this paper.

References

- 1) Yadav JS, Wholey MH, Kuntz RE, et al: Protected carotid-artery stenting versus endarterectomy in high-risk patients. *N Engl J Med* 2004; 351: 1493–1501.
- 2) Jongen LM, Hendrikse J, Waaijer A, et al: Frequency and consequences of early in-stent lesions after carotid artery stent placement. *J Vasc Interv Radiol* 2009; 20: 573–579.
- 3) Chaturvedi S, Yadav JS: The role of antiplatelet therapy in carotid stenting for ischemic stroke prevention. *Stroke* 2006; 37: 1572–1577.
- 4) Kim KS, Fraser JF, Grupke S, et al: Management of antiplatelet therapy in patients undergoing neuroendovascular procedures. *J Neurosurg* 2018; 129: 890–905.
- 5) Price MJ, Berger PB, Teirstein PS, et al: Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. *JAMA* 2011; 305: 1097–1105.
- 6) George G, Patel N, Jang C, et al: Proteinuria predicts resistance to antiplatelet therapy in ischemic stroke. *Transl Stroke Res* 2018; 9: 130–134.
- 7) Furtado RHM, Giugliano RP, Dalcoquio TF, et al: Increased bodyweight and inadequate response to aspirin in individuals with coronary artery disease. *J Thromb Thrombolysis* 2019; 48: 217–224.
- 8) Lee JH, Cha JK, Lee SJ, et al: Addition of cilostazol reduces biological aspirin resistance in aspirin users with ischaemic stroke: a double-blind randomized clinical trial. *Eur J Neurol* 2010; 17: 434–442.
- 9) Su J, Li X, Yu Q, et al: Association of P2Y12 gene promoter DNA methylation with the risk of clopidogrel resistance in coronary artery disease patients. *Biomed Res Int* 2014; 2014: 450814.
- 10) Khanna V, Mikael R, Thayalasamy K, et al: Does the response to aspirin and clopidogrel vary over 6 months in patients with ischemic heart disease? *J Thromb Haemost* 2015; 13: 920–930.
- 11) Buch AN, Singh S, Roy P, et al: Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention. *Am J Cardiol* 2007; 99: 1518–1522.
- 12) Diener HC, Bogousslavsky J, Brass LM, et al: Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. *Lancet* 2004; 364: 331–337.
- 13) Daou B, Starke RM, Chalouhi N, et al: P2Y12 reaction units: effect on hemorrhagic and thromboembolic complications in patients with cerebral aneurysms treated with the pipeline embolization device. *Neurosurgery* 2016; 78: 27–33.
- 14) Yaseen IF, Farhan HA, Abbas HM: Clopidogrel non-responsiveness in patients undergoing percutaneous coronary intervention using the VerifyNow test: frequency and predictors. *Eur J Hosp Pharm* 2019; 26: 113–116.
- 15) Lin M, Todaro M, Chan J, et al: Association between CYP2C19 polymorphisms and outcomes in cerebral endovascular therapy. *AJNR Am J Neuroradiol* 2016; 37: 108–113.
- 16) Wadowski PP, Kopp CW, Koppensteiner R, et al: Decreased platelet inhibition by P2Y12 receptor blockers in anaemia. *Eur J Clin Invest* 2018; 48. doi: 10.1111/eci.12861
- 17) Gremmel T, Mueller M, Koppensteiner R, et al: Liver function is associated with response to clopidogrel therapy in patients undergoing angioplasty and stenting. *Angiology* 2016; 67: 835–839.
- 18) Watanabe Y, Kozuma K, Ishikawa S, et al: Hyper-response to clopidogrel in Japanese patients undergoing transcatheter aortic valve implantation. *Int Heart J* 2016; 57: 190–197.
- 19) Delgado Almandoz JE, Kadkhodayan Y, Crandall BM, et al: Variability in initial response to standard clopidogrel therapy, delayed conversion to clopidogrel hyper-response, and associated thromboembolic and hemorrhagic complications in patients undergoing endovascular treatment of unruptured cerebral aneurysms. *J Neurointerv Surg* 2014; 6: 767–773.
- 20) Kayan Y, Delgado Almandoz JE, Fease JL, et al: Efficacy of a two-test protocol for achieving a therapeutic response to clopidogrel prior to elective endovascular intracranial

- aneurysm treatment and an 'induced' postoperative hyper-response. *J Neurointerv Surg* 2017; 9: 792–796.
- 21) Tello-Montoliu A, Rivera J, Hernández D, et al: Temporal changes in platelet response in acute coronary syndrome patients with prasugrel and clopidogrel after stent implantation. *Circ J* 2018; 82: 353–360.
- 22) Yang A, Pon Q, Lavoie A, et al: Long-term pharmacodynamic effects of Ticagrelor versus clopidogrel in fibrinolytic-treated STEMI patients undergoing early PCI. *J Thromb Thrombolysis* 2018; 45: 225–233.
- 23) Lee DH, Kim HS, Kim SM, et al: Change of platelet reactivity to antiplatelet therapy after stenting procedure for cerebral artery stenosis: VerifyNow antiplatelet assay before and after stenting. *Neurointervention* 2012; 7: 23–26.
- 24) North American Symptomatic Carotid Endarterectomy Trial Collaborators, Barnett HJM, Taylor DW, et al: Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. *N Engl J Med* 1991; 325: 445–453.
- 25) Tokuda R, Yoshimura S, Uchida K, et al: Real-world experience of carotid artery stenting in Japan: analysis of 8458 cases from the JR-NET3 Nationwide Retrospective Multi-center Registries. *Neurol Med Chir (Tokyo)* 2019; 59: 117–125.
- 26) Katzman BM, Wockenfus AM, Scott RJ, et al: Estimating short- and long-term reference change values and index of individuality for tests of platelet function. *Clin Biochem* 2019; 74: 54–59.
- 27) Muller O, Hamilos M, Bartunek J, et al: Relation of endothelial function to residual platelet reactivity after clopidogrel in patients with stable angina pectoris undergoing percutaneous coronary intervention. *Am J Cardiol* 2010; 105: 333–338.
- 28) Schofer J, Arendt M, Tübler T, et al: Late cerebral embolization after emboli-protected carotid artery stenting assessed by sequential diffusion-weighted magnetic resonance imaging. *JACC Cardiovasc Interv* 2008; 1: 571–577.
- 29) Qureshi AI, Luft AR, Janardhan V, et al: Identification of patients at risk for periprocedural neurological deficits associated with carotid angioplasty and stenting. *Stroke* 2000; 31: 376–382.
- 30) Lev EI, Patel RT, Maresh KJ, et al: Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. *J Am Coll Cardiol* 2006; 47: 27–33.